12th Investigator Initiated Trials

NEW IIT CONTENT INCLUDES AGGREGATE SPEND, M&A, EMERGING MARKETS, PUBLICATION PLANNING AND MORE!

JOIN US AND LEARN BEST PRACTICES WITH OUR SPEAKING FACULTY INCLUDING PARTICIPATION FROM THE FOLLOWING ORGANIZATIONS:

    * Abbott Laboratories
    * Allergan
    * Astrazeneca
    * Celgene
    * Centocor
    * IISRA
    * Johnson & Johnson
    * Merck
    * Millenium
    * Pfizer
    * Vertex Pharmaceuticals
  

"The Original Conference Returns with Key Sessions,
Relevant Case Studies and a Review of
Health Care Reform's Impact on IIT's"

Sample of Topics to be Addressed Include:

• Examining Compliance Challenges of Tracking Aggregate Spend
• Managing Aggregate Spend Master Data
• Maintaining The Integrity Of Trials Obtained in Mergers and Acquisitions
• Cutting Costs and Streamlining The IIT Approval Process While Minimizing Industry’s Carbon Footprint
• Implementing a Competitive Grant Program in Place of an IIT
• Understanding the Role of Publication Planning as it relates to IITs

Testimonials from ExL’s Investigator-Initiated Trial Series:

"It was one of the best conferences I have attended and felt that it provided a lot of valuable information."
Diana Fraser-Myers, Medtronic Cardio Vascular

"That’s what I love about you guys – you not only put on a great conference, but you really care about your attendees!"
Vallyn Nieves, Solvay Pharmaceuticals

"Thanks, I sure learned a lot and made great contacts!"
~ Aubrey Kelly, Amgen

"Yes – Great Networking Opportunity"
~ Veronica Rodriguez, Elan

"Overall Great Presentations! Nothing missing from my point of view"
~ Ylva Sjoquist, Ikaria

"Very good presentation! I learned a lot"
~ Tamara Gaymon, INO Therapeutics

"Thanks – once again, great job!"
~ Karen Bartels, AstraZeneca

"Great meeting this year"
~ Amy Jansen, UCB